In 2006, researchers at Micromet — a small biotech with US headquarters in Bethesda, Md. — started up a human clinical trial on a novel type of antibody to treat cancer. As their CEO, Christian Itin knew of the compound's potential and had ushered it through many developmental growing pains. After the first round of dosing, patients were experiencing the typical symptoms of an immune response, such as chills and fever, which suggested that the antibody was working.
Survey Series
For Advertisers
Reinventing the Antibody
Coming up with an entirely new approach to cancer therapy can be a headache, as Micromet's Christian Itin has learned.
(continued >>)
To continue reading this full article, you must be a subscriber to The Scientist.
You are only a few minutes away from unlimited access.
If you already have an online subscription, please Log-In Now.
New to The Scientist? Register to get access to a selection of our content, interactive features and useful tools free without a subscription.
New to The Scientist? Register to get access to a selection of our content, interactive features and useful tools free without a subscription.
Subscribe to The Scientist to get unlimited access to our premium content
Get unlimited access to this article and over 20 years of The Scientist archives. You won’t miss a word – all for as little as $4.95. Subscribe now.The Scientist offers site licenses to institutions and organizations. Recommend us to your librarian and get online access through your place or work or study.